GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Orpea SA (XPAR:ORP) » Definitions » EBITDA

Orpea (XPAR:ORP) EBITDA : €2,650 Mil (TTM As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Orpea EBITDA?

Orpea's EBITDA for the six months ended in Dec. 2023 was €2,363 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €2,650 Mil.

During the past 3 years, the average EBITDA Growth Rate was 43.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Orpea was 43.80% per year. The lowest was 6.10% per year. And the median was 19.05% per year.

Orpea's EBITDA per Share for the six months ended in Dec. 2023 was €18.07. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2023 was €301.78.

During the past 3 years, the average EBITDA per Share Growth Rate was -32.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Orpea was 33.90% per year. The lowest was -32.70% per year. And the median was 16.00% per year.


Orpea EBITDA Historical Data

The historical data trend for Orpea's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orpea EBITDA Chart

Orpea Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 958.75 942.13 961.19 -3,451.59 2,802.60

Orpea Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 466.06 190.94 -3,642.53 287.11 2,362.52

Competitive Comparison of Orpea's EBITDA

For the Medical Care Facilities subindustry, Orpea's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orpea's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Orpea's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Orpea's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Orpea's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Orpea's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, Orpea's EBITDA was €2,803 Mil.

Orpea's EBITDA for the quarter that ended in Dec. 2023 is calculated as

Orpea's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2023, Orpea's EBITDA was €2,363 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2,650 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Orpea  (XPAR:ORP) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Orpea EBITDA Related Terms

Thank you for viewing the detailed overview of Orpea's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Orpea (XPAR:ORP) Business Description

Traded in Other Exchanges
Address
12, Rue Jean Jaures, CS 10032, Puteaux Cedex, Paris, FRA, 92 813
Orpea SA operates a network of long-term, post-acute, psychiatric, and home care facilities in Europe. The majority of the firm's revenue is generated in France. Orpea's long-term care facilities are primarily nursing homes, though it also provides serviced residences for autonomous and semi-autonomous elderly patients. Orpea's post-acute and rehabilitation facilities specialize in geriatrics, musculoskeletal conditions, cardiovascular conditions, nervous system diseases, and, Haematology and oncology. Its psychiatric clinics provide treatment and psychotherapeutic monitoring for a range of conditions.

Orpea (XPAR:ORP) Headlines

No Headlines